Supply Chain Pulse — 2026-08-01
Supply Chain Pulse — 2026-08-01
Here are today's top healthcare supply chain stories.
Massachusetts bans certain chemicals in IV medical devices
Massachusetts Gov. Maura Healey has signed legislation banning the manufacture, sale and distribution of certain intravenous medical devices made with intentionally added DEHP, a phthalate used in som
Source: Becker's Hospital Review - Supply Chain
Boston Scientific to cut jobs in $700M+ restructuring
Marlborough, Mass.-based Boston Scientific’s board of directors approved a global restructuring initiative July 21 that is expected to cost up to $800 million and result in job cuts, according to a Ju
Source: Becker's Hospital Review - Supply Chain
Hospital supply chain costs to rise in 2027: 5 notes
Hospital supply chain costs are projected to increase 3.39% in 2027 as health systems contend with continued margin pressure and uneven inflation across nonlabor spending categories, according to a Ju
Source: Becker's Hospital Review - Supply Chain
MedSurg demand shifts will reshape supply planning: Vizient
Health systems should prepare for shifting MedSurg demand in 2027, according to a new Vizient outlook. The report, published July 27, says evolving care delivery models, treatment pathways and supply
Source: Becker's Hospital Review - Supply Chain
Where AI is delivering the biggest supply chain wins
Artificial intelligence is improving healthcare supply chains, but not in the flashy ways many expected. Rather than replacing procurement teams or making purchasing decisions autonomously, supply cha
Source: Becker's Hospital Review - Supply Chain
10 systems seeking supply chain leaders
As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems across the country are hiring for senior-level supply chai
Source: Becker's Hospital Review - Supply Chain
Johnson & Johnson embarks on supply chain restructuring
The project, which is largely tied to the innovative medicine segment, will see the company exit certain facilities and incur costs of up to $750 million.
Source: Supply Chain Dive - Healthcare
FDA Reports False Positive Cyclospora Test for Taylor Farms Lettuce
Despite the false positive, the company still remains a target of the investigation into the outbreak, and people should not eat recalled lettuce.
Source: Healthcare Purchasing News
HRSA unveils 340B rebates 2.0
The 340B Drug Discount Program rebate demonstration applies to medicines that represented less than 5.5% of 340B sales in 2025.
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe